1. Short title This Act may be cited as the Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020 . 2. Table of contents The table of contents of this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. Title I—Health provisions Sec. 101. Report to Congress on barriers to domestic manufacturing of medical products and supplies. Sec. 102. Enhance intraagency coordination and public health assessment with regard to compliance activities. Sec. 103. Encouraging international harmonization. Sec. 104. Mutual recognition agreements for inspections and review activities. Sec. 105. Enhancing transparency of drug facility inspection timelines. Sec. 106. Advanced manufacturing technologies program. Title II—Tax incentives to increase domestic pharmaceutical and medical device production Sec. 201. Credit for pharmaceutical and medical device production activities in distressed zones. I Health provisions 101. Report to Congress on barriers to domestic manufacturing of medical products and supplies (a) Report Not later than January 1, 2021, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on barriers to domestic manufacturing of active pharmaceutical ingredients, drugs, and devices that are sourced or manufactured outside of the United States. (b) Contents Such report shall— (1) identify factors that limit or otherwise discourage the domestic manufacturing of active pharmaceutical ingredients, drugs, and devices that are currently sourced or manufactured outside of the United States, including any Federal, State, local, or Tribal laws and regulations that hinder domestic manufacturing opportunities